english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2019 > The Prescrire Information Awards for 2019 > 2019 Information Awards

The Prescrire Awards for 2019

The Prescrire Information Awards for 2019

The Prescrire Information Awards for 2019

Les Palmarès Prescrire Prescrire's editors requested information from 112 drug companies in 2019. Six, who chose to be transparent, are on the "Honours List". Others responded too little, too irregularly or not at all, earning them a "Red Card".
Out of 112 companies contacted by Prescrire:


Palmarès Info : Firmes à l'honneur

On the Honours List

 
OUTSTANDING:


  • EG Labo


FOLLOWED BY:

  • Arrow Génériques
  • Bioprojet Pharma
  • Bouchara Recordati
  • GlaxoSmithKline
  • Vectans Pharma


Palmarès Info : Lanternes Rouges

Red Cards

• Alk Abelló
• Bayer Healthcare
• Biogaran
• Genévrier
• GMP Orphan
• Janssen Cilag
• Kyowa Kirin Pharma
• Menarini
• MSD
• Otsuka Pharmaceutical
• Sandoz
• Takeda
• Teva Santé
• Vifor

In 2019, Prescrire's editors requested information from 112 companies. Some companies choose to be transparent with Prescrire, and demonstrate this by sending quality information that is relevant to Prescrire's requests. 6 such companies were placed on the "Honours List" for 2019. Only one among them provided useful, detailed data early on, and sometimes without being asked, and was hence recognised as "Outstanding".

Other drug companies failed to respond, or responded too little, or too irregularly, to Prescrire's requests for information. Some of them delayed their response, and then failed to provide usable information. Some omitted the most relevant or sensitive data. "Red Cards" are given when too many such failings pile up. 14 drug companies were given a Red Card for 2019.
 

For details, download the full review:

 FREE  "The Prescrire Awards for 2019" Prescrire Int 2020; 29 (213): 77-81. (Pdf, free)

> Rules governing the Prescrire Awards (pdf, in French)

Back to the contents page for the 2019 Prescrire Awards >

 ©Prescrire 1 February 2020 Share Share on Facebook Share on Twitter